Systemic sclerosis (scleroderma): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 46
• BCMA 25
• CD20 5
• JAK 0
• STAT3 0
• mTOR 0
• PPAR 0
• PD-1 1
• STING 0
• IL-17 0
• IL-6 0
• NLRP3 0
• CTLA-4 1
• CXCR4 0
• HMGB1 0
• IL-13 0
• IL-4 0
• NRF2 0
• PD-L1 1
• RUNX1 0
• SGLT2 0
• AKT 0
• CD123 0
• CD30 0
• CD38 1
• FGFR 0
• G6PD 0
• GLP-1 0
• HIF-1 0
• IL-15 1
• MMP-9 0
• PARP 0
• PI3K 0
• SIRT1 0
• TLR4 0
• TNF 0
• TP53 0
• TREM2 0
• TYK2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 25+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

  NCT07361094· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

• Suspended

  Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis

  NCT06792344· The Children's Hospital of Zhejiang University School of Medicine· Updated 8 Sept 2026

  “temporarily suspended due to no new subjects at present”Registry text, quoted unchanged. Source

• Terminated

  KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

  NCT06400303· Kyverna Therapeutics· Updated 31 Aug 2026

  “Study discontinued due to sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases

  NCT06913608· Calibr, a division of Scripps Research· Updated 5 Mar 2026

  “Business Decision”Registry text, quoted unchanged. Source

• Suspended

  Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases

  NCT06549296· Nanjing Bioheng Biotech Co., Ltd.· Updated 3 Feb 2026

  “R\&D strategy adjustment”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

  NCT06377228· Takeda· Updated 6 Apr 2025

  “Business decision (no safety concerns)”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of AZD0120 in Autoimmune Diseases

  NCT07295847· AstraZeneca· Source

• A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

  NCT07873931· Bristol-Myers Squibb· Source

• A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

  NCT05869955· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

  NCT07115745· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases

  NCT06503224· The First Affiliated Hospital of University of Science and Technology of China· Source

• A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

  NCT06377228· Takeda· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 10
• Mendelian Randomization Analysis 8
• Gene Expression Profiling 14
• Sequence Analysis, RNA 3
• Exome Sequencing 1
• Proteomics 11
• Metabolomics 6
• Mass Spectrometry 2
• Flow Cytometry 9
• Immunohistochemistry 2
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 26
• Machine Learning 7
• Deep Learning 3
• Cohort Studies 42
• Genome-Wide Association Study 13

• A compact five-gene immuno-fibrotic profile distinguishing systemic sclerosis subtypes with PXDN validated as a fibrosis-associated target.

  Front Immunol, Aug 2026

• Advanced imaging in systemic sclerosis: distinguishing activity from damage across organ systems.

  Curr Opin Rheumatol, Aug 2026

• Development and internal validation of an interpretable machine learning model using routine laboratory data for systemic sclerosis-associated pulmonary arterial hypertension.

  Rheumatol Int, Jul 2026

• Self-Paced Learning for Images of Antinuclear Antibodies.

  IEEE Trans Med Imaging, Apr 2026

• Spectroscopic and machine learning approaches for clinical subtyping in systemic sclerosis.

  Sci Rep, Feb 2026

• Exploratory Machine Learning Prioritizes Shared Blood Transcriptional Candidate Genes and Immune Correlates Across Antiphospholipid Syndrome and Systemic Sclerosis.

  Biomed Res Int, Jan 2026

• Metabolomic and machine learning enhances patient diagnosis and stratification in systemic autoimmune diseases.

  Comput Biol Med, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.